Fmr LLC Purchases 179,374 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Fmr LLC increased its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 3.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 4,899,134 shares of the company’s stock after purchasing an additional 179,374 shares during the period. Fmr LLC owned approximately 0.12% of Keros Therapeutics worth $284,493,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. KBC Group NV grew its holdings in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics during the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics during the second quarter valued at approximately $128,000. Finally, LMR Partners LLP purchased a new position in Keros Therapeutics during the third quarter valued at approximately $213,000. 71.56% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on KROS. Guggenheim initiated coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 target price on the stock. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. Scotiabank assumed coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Trading Down 1.4 %

NASDAQ:KROS opened at $57.74 on Monday. Keros Therapeutics, Inc. has a twelve month low of $27.31 and a twelve month high of $73.00. The company has a market cap of $2.34 billion, a PE ratio of -11.08 and a beta of 1.23. The company’s 50 day moving average is $59.49 and its two-hundred day moving average is $52.28.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.33) earnings per share. As a group, analysts expect that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.